Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus.

摘要: As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs be assessed. Hepatitis virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims estimate comparative cost-effectiveness two recently licenced interferon-free 3. Utilising a published Markov model results matching-adjusted indirect comparison clinical trial data (ALLY-3 VALENCE, respectively), 12 weeks daclatasvir + sofosbuvir (DCV + SOF) was compared 24 weeks sofosbuvir + ribavirin (SOF + RBV). UK-specific inputs were used inform cost-utility these regimens. In base case analysis, DCV + SOF found dominant over SOF + RBV in treatment-naive patients, patients that had previously been treated, intolerant to, or ineligible for, Given low rates currently observed UK, also no interferon-ineligible/intolerant may considered cost-effective an incremental ratio £8817. When SOF + RBV, improved quality life reduced total costs, therefore likely represent significant economic value as option infection.